SAN FRANCISCO, Aug. 31, 2024 (GLOBE NEWSWIRE) -- Hagens Berman Outset Medical (NASDAQ: OM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may assist the investigation to contact its attorneys. Class Period: Aug. 1, 2022 – Aug. 7, 2024Lead Plaintiff Deadline: Oct. 28, 2024Visit: www.hbsslaw.com/investor-fraud/om Contact the Firm Now: OM@hbsslaw.com 844-916-0895 Outset Medical, Inc. (OM) Securities Class Action: The litigation focuses ...

NEW YORK, Aug. 31, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Outset Medical, Inc. (NASDAQ: OM) between August 1, 2022 and August 7, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024.So What: If you purchased Outset Medical securities during the Class Pe ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Outset Medical securities between August 1, 2022 and August 7, 2024, both dates inclusive (the “Class Per ...

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Outset Medical, Inc. (“Outset Medical” or the “Company”) (NYSE: OM) securities between August 1, 2022 and August 7, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the ...

ATLANTA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Outset Medical, Inc. (“Outset Medical” or “the Company”) (NASDAQ: OM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) the Tablo products were marketed for continuous renal replacement therapy, which is not one of the indications appr ...

文章核心观点 - 公司的主要产品Tablo系列设备被用于连续性肾脏替代治疗,这并非FDA批准的适应症之一 [1] - 公司可能需要提交额外的510(k)申请以获得Tablo产品的新适应症批准,这存在重大风险 [1] - 公司缺乏足够的销售团队和流程来执行Tablo销售的快速增长 [1] - 上述因素将对公司的收入增长产生不利影响 [1] 根据相关目录分别进行总结 公司业务和产品 - 公司主要产品为Tablo系列设备,用于透析护理,包括Tablo血液透析系统和TabloCart [1] - 公司的Tablo产品被用于连续性肾脏替代治疗,这并非FDA批准的适应症之一 [1] 财务表现 - 公司2024年第二季度财务业绩大幅低于预期,全年收入指引下调390百万美元 [2] - 公司需要采取措施改善执行力,包括销售团队和流程的重组,无法实现之前预测的TabloCart销售增长 [2] 股价表现 - 公司股价在2024年8月8日下跌68.53%,收于每股1.07美元,成交量异常激增 [2]

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Outset Medical securities? If you purchased securities and suffered ...

NEW YORK, Aug. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) on behalf of Outset stockholders. Our investigation concerns whether Outset has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. The investigation focuses on whether the Company issued false and/or mi ...

LOS ANGELES, Aug. 9, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Outset released its second quarter 2024 financial results on August 7, 2024. The ...

Outset Medical (NASDAQ:OM) stock is taking a beating on Thursday after the medical technology company announced earnings results for the second quarter of the year.The Outset Medical earnings report starts with an adjusted EPS of -47 cents. That’s worse than the -43 cents per share that Wall Street was expecting. That’s despite it being better than the -69 cents per share from the same period of the year prior.On top of that, Outset Medical posted revenue of $27.39 million during the quarter. That’s another ...